Data

N-3 fatty acids for improvement in Respiratory Outcomes - the N3RO Trial

Health Data Australia Contributor Records
gould, jacqueline ; Makrides, Maria ; Health Translation SA Enquiries
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58138/M4RW-JC89&rft.title=N-3 fatty acids for improvement in Respiratory Outcomes - the N3RO Trial&rft.identifier=http://doi.org/10.58138/M4RW-JC89&rft.publisher=South Australian Health and Medical Research Institute (SAHMRI)&rft.description=This dataset includes 1273 very preterm infants born at less than 29 weeks of gestation recruited into the N3RO trial. Infants were randomised to receive an enteral DHA or control emulsion from the first 3 days of enteral feeds until 36 weeks postmenstrual age or discharge home, whichever occurred first. Baseline clinical and sociodemographic characteristics of the infants and their families were collected, along with blood spot samples for fatty acid analysis at baseline and 36 weeks postmenstrual age. The primary outcome was bronchopulmonary dysplasia, as assessed by the requirement for supplemental oxygen and/or assisted ventilation at 36 weeks postmenstrual age. Also available are data on secondary clinical outcomes collected during the neonatal hospitalisation. File type is .PDF.&rft.creator=gould, jacqueline &rft.creator=Makrides, Maria &rft.creator=Health Translation SA Enquiries &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000503820&rft.coverage=South Australia Victoria Queensland Western Australia New South Wales&rft_subject=Infant and Child Health&rft_subject=Respiratory Diseases&rft_subject=Reproduction&rft_subject=FOS: Medical biotechnology&rft.type=dataset&rft.language=English Access data via landing page
Cite Saved to MyRDA Save to MyRDA

Full description

This dataset includes 1273 very preterm infants born at less than 29 weeks of gestation recruited into the N3RO trial. Infants were randomised to receive an enteral DHA or control emulsion from the first 3 days of enteral feeds until 36 weeks postmenstrual age or discharge home, whichever occurred first. Baseline clinical and sociodemographic characteristics of the infants and their families were collected, along with blood spot samples for fatty acid analysis at baseline and 36 weeks postmenstrual age. The primary outcome was bronchopulmonary dysplasia, as assessed by the requirement for supplemental oxygen and/or assisted ventilation at 36 weeks postmenstrual age. Also available are data on secondary clinical outcomes collected during the neonatal hospitalisation. File type is .PDF.

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Spatial Coverage And Location

text: South Australia Victoria Queensland Western Australia New South Wales

Subjects
FOS: Medical biotechnology | Infant and Child Health | Reproduction | Respiratory Diseases |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Health Translation SA Enquiries

Other : [email protected]

National Health and Medical Research Council

Crossref Funder ID : https://doi.org/10.13039/501100000925

Identifiers